ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1129

Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever

Admir Öztürk1, Murad Kucur2, Lara Yagci1 and Serdal Ugurlu3, 1Istanbul University - Cerrahpasa, Cerrahpasa Faculty of Medicine, Istanbul, Turkey, 2Istanbul University-Cerrahpasa, Engineering Faculty, Mechanical Engineering Department, Istanbul, Turkey, 3Istanbul University-Cerrahpasa, Istanbul, Turkey

Meeting: ACR Convergence 2024

Keywords: Autoinflammatory diseases, FMF

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 17, 2024

Title: Miscellaneous Rheumatic & Inflammatory Diseases Poster II

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disease caused by mutations in the MEFV gene. Colchicine is the first-line treatment of FMF. Although it is an effective and safe option, %5 – %10 of FMF patients develop resistance to colchicine. To prevent attacks and subclinical inflammation, colchicine-resistant FMF is managed by elevating the colchicine dose or switching to IL-1 inhibitors. Predicting colchicine at the time of diagnosis would be beneficial for preventing amyloidosis and achieving better patient satisfaction by initiating a higher dose of colchicine earlier, preventing subclinical inflammation, and reducing the frequency of attacks. Therefore we aimed to develop machine learning algorithms for predicting colchicine resistance in patients with FMF.

Methods: We conducted an analysis of medical records from 1300 FMF patients, extracting various features including chest pain, presence of compound heterozygous mutations in MEFV gene, presence of M694V homozygous mutation, attacks per month before treatment, age of symptom onset, erysipelas-like rash associated with attacks, presence of arthritis with erythema, presence of recurrent arthritis, and colchicine resistance status.

Results: The cohort included both pediatric and adult-onset FMF patients, with 113(8,6%) classified as colchicine resistant and 1187(91,4%) as colchicine-responsive. Logistic regression exhibited the best performance, utilizing features such as the presence of compound heterozygous mutations in the MEFV gene, chest pain during attacks, number of attacks per month before treatment, M694V homozygous mutation, and presence of recurrent arthritis, achieving an AUC of 0.76. (Figure 1) Deep neural network models also performed well, with the features of the number of attacks per month before treatment, the presence of M694V homozygous mutation, and the presence of recurrent arthritis, yielding an AUC of 0.75. (Figure 2)(Table 1)

Conclusion: Machine learning algorithms, offering a probability output for colchicine resistance risk, can function as sensitive and specific tests with adaptable thresholds. Enhancing AUC may require training deep learning models on larger datasets or incorporating additional features associated with colchicine resistance risk.

Supporting image 1

ROC Curve of Logistic Regression Model (AUC = 0.76)

Supporting image 2

ROC Curve of Deep Learning Model (AUC = 0.75)

Supporting image 3

Summary of the Results of Machine Learning Models


Disclosures: A. Öztürk: None; M. Kucur: None; L. Yagci: None; S. Ugurlu: None.

To cite this abstract in AMA style:

Öztürk A, Kucur M, Yagci L, Ugurlu S. Machine Learning Algorithms to Predict Colchicine Resistance in Familial Mediterranean Fever [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/machine-learning-algorithms-to-predict-colchicine-resistance-in-familial-mediterranean-fever/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/machine-learning-algorithms-to-predict-colchicine-resistance-in-familial-mediterranean-fever/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology